Article
Multidisciplinary Sciences
Dominique F. Leitner, Evgeny Kanshin, Manor Askenazi, Yik Siu, Daniel Friedman, Sasha Devore, Drew Jones, Beatrix Ueberheide, Thomas Wisniewski, Orrin Devinsky
Summary: This pilot study found that short-term everolimus before epilepsy surgery in TSC and FCD resulted in no adverse events and trending lower mTOR signaling (phospho-S6). Future studies should evaluate implications of our findings, including coagulation system activation and everolimus efficacy in FCD, in larger studies with long-term treatment to better understand molecular and clinical effects.
Article
Medicine, General & Internal
Sebastian Wolf, Verena S. Hoffmann, Florian Sommer, Matthias Schrempf, Mingming Li, Martin Ryll, Ulrich Wirth, Matthias Ilmer, Jens Werner, Joachim Andrassy
Summary: Based on network meta-analysis, ERL combined with CNI showed the strongest anti-CMV effect compared to regular CNI treatment (RR 0.27, CI 0.22-0.32, p <0.0001).
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Tomasz Switaj, Aleksandra Sobiborowicz, Pawel Teterycz, Anna Klimczak, Donata Makula, Michal Wagrodzki, Anna Szumera-Cieckiewicz, Piotr Rutkowski, Anna M. Czarnecka
Summary: The study demonstrates that sirolimus is an effective first-line treatment for PEComa patients, with a high objective response rate of 73% and disease control achieved in all patients. The 5-year overall survival rate was 65%, indicating promising long-term efficacy of targeted therapy for PEComa.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
David E. Kandzari, Jacques J. Koolen, Gheorghe Doros, Hector M. Garcia-Garcia, Johan Bennett, Ariel Roguin, Elie G. Gharib, Donald E. Cutlip, Ron Waksman
Summary: This study compared the late-term (5-year) clinical outcomes of ultra-thin strut bioresorbable polymer sirolimus-eluting stents (BP SES) with thin strut durable polymer everolimus-eluting stents (DP EES). The results showed that BP SES was associated with a lower occurrence of target vessel-related myocardial infarction and late/very late definite/probable stent thrombosis.
JACC-CARDIOVASCULAR INTERVENTIONS
(2022)
Article
Oncology
Alyce Mei-Shiuan Kuo, Stephanie Gu, Joseph Stoll, Andrea P. Moy, Stephen W. Dusza, Allison Gordon, Elena C. Haliasos, Yelena Janjigian, Lukas Kraehenbuehl, Elizabeth A. Quigley, Paul Chapman, Mario E. Lacouture, Alina Markova
Summary: Immune checkpoint inhibitors (ICI) can effectively target cancer cells, but they may also cause immune-related cutaneous adverse events (ircAEs) in a significant number of patients. This study examined the use of dupilumab for treating ICI-associated ircAEs and found that 87% of patients responded to the treatment, with 44.1% achieving complete resolution of the adverse events.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Infectious Diseases
Delia Mercedes Bianco, Flavio De Maio, Giulia Santarelli, Ivana Palucci, Alessandro Salustri, Giada Bianchetti, Giuseppe Maulucci, Franco Citterio, Maurizio Sanguinetti, Enrica Tamburrini, Michela Sali, Giovanni Delogu
Summary: Despite being investigated as a host-directed therapy in treating tuberculosis, Everolimus showed no direct or indirect activity against Mycobacterium tuberculosis (Mtb). Even in an immunosuppressed patient, Everolimus did not affect the viability of Mtb and had minimal impact in host cells during infection. This case emphasizes the importance of careful drug repurposing and pre-clinical experimental studies.
Article
Immunology
Morgan Vandermeulen, Pauline Erpicum, Noella Bletard, Laurence Poma, Francois Jouret, Olivier Detry
Summary: This study evaluated the effects of MSCs in combination with everolimus on Treg expansion and liver graft tolerance in a rat model of liver transplantation. The results showed that the combination of MSCs with everolimus did not have a synergistic effect in preventing acute rejection.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Pharmacology & Pharmacy
Manuel Ramos-Casals, Alejandra Flores-Chavez, Pilar Brito-Zeron, Olivier Lambotte, Xavier Mariette
Summary: Immunotherapies are effective treatments for inflammatory diseases, but their use has been linked to the development of autoimmune disorders. The use of immunotherapies in solid cancer patients has dramatically changed the scenario, causing collateral side effects on the immune system. The broad pharmacological and phenotypic scenario of immune-related adverse events (irAEs) associated with kinase inhibitors needs more research from a multidisciplinary perspective.
PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Immunology
Qinan Yin, Liuyun Wu, Lizhu Han, Xingyue Zheng, Rongsheng Tong, Lian Li, Lan Bai, Yuan Bian
Summary: Since the development of the first Immune Checkpoint Inhibitor, tumor immunotherapy has advanced significantly, leading to improved response rate and survival rate in many cancers. However, resistance and immune-related adverse events remain as challenges in achieving lasting response. This article summarizes the mechanisms of immune checkpoint inhibitors, different types of immune-related adverse events, and provides strategies and targets for prevention and therapeutic interventions.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Omar Fahmy, Osama A. A. Ahmed, Mohd Ghani Khairul-Asri, Nabil A. Alhakamy, Waleed S. Alharbi, Usama A. Fahmy, Mohamed A. El-Moselhy, Claudia G. Fresta, Giuseppe Caruso, Filippo Caraci
Summary: The combination of durvalumab and tremelimumab has a higher risk of treatment discontinuation, mortality, fever, diarrhea, rash, pruritis, and reduced appetite compared to durvalumab monotherapy. This information is crucial for patients enrolled in clinical trials involving this combined therapy.
Article
Endocrinology & Metabolism
Federica Mangili, Emanuela Esposito, Donatella Treppiedi, Rosa Catalano, Giusy Marra, Genesio Di Muro, Anna Maria Barbieri, Marco Locatelli, Andrea G. Lania, Alessandra Mangone, Anna Spada, Maura Arosio, Erika Peverelli, Giovanna Mantovani
Summary: This study found that cabergoline can overcome the resistance to everolimus and inhibit cell proliferation in NF-PitNETs and prolactin-secreting tumors by suppressing AKT activation. The combination of cabergoline may improve the anti-tumoral activity of mTOR inhibitors, providing a new treatment option for certain resistant pituitary neuroendocrine tumors.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Immunology
Ning Jiang, Yue Yu, Min Zhang, Yu Tang, Dawei Wu, Shuhang Wang, Yuan Fang, Yu Zhang, Lin Meng, Yingying Li, Huilei Miao, Peiwen Ma, Huiyao Huang, Ning Li
Summary: This study found that specific HLA types may be associated with irAEs in specific organs and tissues, while HLA heterogeneity does not significantly influence the occurrence of irAEs.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Kang Liu, Zhongke Qin, Xueqiang Xu, Ting Li, Yifei Ge, Huijuan Mao, Changying Xing
Summary: The study analyzed 95 eligible randomized controlled trials involving 40,552 participants and found that both ICI-based regimens and traditional cancer therapies had a higher risk of RAEs and AKI compared to placebo. Among the various ICI therapies, anti-CTLA-4 appeared to be associated with increased toxicity, while anti-PD-1 was safer.
FRONTIERS IN ONCOLOGY
(2021)
Review
Gastroenterology & Hepatology
Xiangyu Yan, Songhan Huang, Yang Yang, Ziwen Lu, Feiyu Li, Liyong Jiang, Yong Jiang, Jun Liu
Summary: This systematic review and meta-analysis found that the use of mammalian target of rapamycin (mTOR) inhibitors, sirolimus (SRL) or everolimus (EVL), as immunosuppressants in liver transplantation (LT) recipients with hepatocellular carcinoma (HCC) improved overall survival (OS) and recurrence-free survival (RFS) while reducing the risk of renal toxicity.
LIVER TRANSPLANTATION
(2022)
Review
Oncology
Andrew Nashed, Shijun Zhang, Chien-Wei Chiang, M. Zitu, Gregory A. Otterson, Carolyn J. Presley, Kari Kendra, Sandip H. Patel, Andrew Johns, Mingjia Li, Madison Grogan, Gabrielle Lopez, Dwight H. Owen, Lang Li
Summary: Examining irAEs, particularly gastrointestinal and pulmonary, through ICD data leads to underrepresentation of true irAEs and overrepresentation of false irAEs. Using ICD claims data alone is not a suitable approach for electronic health record data mining for irAEs in immunotherapy clinical research.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Immunology
Peter Vink, Josep Maria Ramon Torrell, Ana Sanchez Fructuoso, Sung-Joo Kim, Sang-Il Kim, Jeff Zaltzman, Fernanda Ortiz, Josep Maria Campistol Plana, Ana Maria Fernandez Rodriguez, Henar Rebollo Rodrigo, Magda Campins Marti, Rafael Perez, Francisco Manuel Gonzalez Roncero, Deepali Kumar, Yang-Jen Chiang, Karen Doucette, Lissa Pipeleers, Maria Luisa Aguera Morales, Maria Luisa Rodriguez-Ferrero, Antonio Secchi, Shelly A. McNeil, Laura Campora, Emmanuel Di Paolo, Mohamed El Idrissi, Marta Lopez-Fauqued, Bruno Salaun, Thomas C. Heineman, Lidia Oostvogels, Caldara Rossana, Carmellini Mario, Chen Yen-Ta, Garibotto Giacomo, Gonzalez Montes Esther, Kanaan Nada, Kuypers Dirk, Lin Cheng-Chia, Maggiore Umberto, Navratil Pavel, Van der Tol Arjan, Villate Navarro Jose Ignacio, Virgilio Bice, Wu Ming-Ju
CLINICAL INFECTIOUS DISEASES
(2020)
Article
Surgery
Paloma L. Martin-Moreno, Ana Sanchez-Fructuoso, Auxiliadora Mazuecos, Marisa Mir, Isabel Lopez-Lopez, Ana Gonzalez-Rinne, Armando Coca, Rosalia Valero, Ana Ventura Galiano, Natalia Ridao, Nestor G. Toapanta-Gaibor, Ernesto Fernandez-Tagarro, Leonidas Cruzado-Vega, Monica Perez-Mir, Carlos Jimenez
Summary: The study found that the offspring of male kidney transplant recipients under MPA had a lower incidence of miscarriages compared to the general population, and a similar incidence of birth defects. No typical embryopathy profile was found, making it difficult to associate the birth defects with the use of MPA. The study suggests a reconsideration of recommendations for males by European and Spanish agencies.
CLINICAL TRANSPLANTATION
(2021)
Review
Immunology
Elena Valdes Franci, Isabel Perez Flores, Francisco Javier Candel, Maria Angeles Moreno de la Higuera, Natividad Calvo Romero, Beatriz Rodriguez Cubillo, Rafael Lucena Valverde, Ana Isabel Sanchez Fructuoso
Summary: HPS, a rare complication in transplant patients, leads to compromised immune function and susceptibility to severe infections. Prompt diagnosis and treatment of underlying infections are crucial for management.
TRANSPLANT INFECTIOUS DISEASE
(2021)
Review
Medicine, General & Internal
Juan M. Buades, Lourdes Craver, Maria Dolores Del Pino, Mario Prieto-Velasco, Juan C. Ruiz, Mercedes Salgueira, Patricia de Sequera, Nicanor Vega
Summary: Diabetic kidney disease is the leading cause of kidney failure, with varying rates of kidney replacement therapy. Late referral to nephrology services increases the risk of adverse outcomes. Managing diabetes with severely reduced kidney function is challenging, requiring careful consideration of treatment options.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Urology & Nephrology
Marina de Cos Gomez, Maria Teresa Garcia Unzueta, Adalberto Benito Hernandez, Alejandro Aguilera Fernandez, Mario Perez Arnedo, Covadonga Lopez del Moral Cuesta, Maria Kislikova, Rosalia Valero San Cecilio, Juan Carlos Ruiz San Millan, Emilio Rodrigo Calabia
Summary: This study compared the utility of pretransplant cardiac troponin I (cTNI) and growth differentiation factor 15 (GDF-15) as biomarkers for predicting events after kidney transplant. The results showed that GDF-15 may be a better predictor of mortality and cardiovascular events compared to cTNI.
AMERICAN JOURNAL OF NEPHROLOGY
(2022)
Article
Surgery
Constantino Fernandez Rivera, Maria Calvo Rodriguez, Jose Luis Poveda, Julio Pascual, Marta Crespo, Gonzalo Gomez, Sheila Cabello Pelegrin, Javier Paul, Ricardo Lauzurica, Monica Perez Mir, Francesc Moreso, Manel Perello, Amado Andres, Esther Gonzalez, Ana Fernandez, Alicia Mendiluce, Beatriz Fernandez Carbajo, Ana Sanchez Fructuoso, Natividad Calvo, Alejandro Suarez, Gabriel Bernal Blanco, Antonio Osuna, M. Carmen Ruiz-Fuentes, Edoardo Melilli, Nuria Montero Perez, Ana Ramos, Beatriz Fernandez, Veronica Lopez, Domingo Hernandez
Summary: In a multicenter, prospective observational study, once-daily tacrolimus formulations were compared in de novo kidney transplant recipients. The LCPT group showed higher relative bioavailability than PR-Tac, with similar effectiveness in preventing rejection and comparable effects on renal function, safety, adherence, treatment failure, and discontinuation rates.
CLINICAL TRANSPLANTATION
(2022)
Article
Urology & Nephrology
Jesus Delgado, Marina Alonso-Riano, Emilio Berna-Rico, Juncal Perez-Somarriba, Khatuna Khmaladze, Jose Antonio Cortes, Ana Sanchez-Fructuoso, Alejandro Pascual
Summary: Metastatic disease in the kidney is rare, especially intraglomerular metastases. This case report describes the finding of intraglomerular metastases in a patient with malignant melanoma in partial remission, emphasizing the importance of considering this condition in cases of rapidly progressive kidney failure.
AMERICAN JOURNAL OF KIDNEY DISEASES
(2022)
Article
Immunology
Beatriz Rodriguez-Cubillo, M. Angeles Moreno de la Higuera, Isabel Perez-Flores, Natividad Calvo Romero, Arianne Sofia Aiffil, Ana Arribi Vilela, Belen Peix, Sara Huertas, Almudena Juez, Ana Sanchez-Fructuoso
Summary: Vaccinated renal transplant recipients who achieve at least a low antibody titer (>20 AU/mL) have better outcomes in terms of pneumonia and mortality compared to unvaccinated recipients. A high antibody titer (>100 AU/mL) is associated with even better outcomes than patients with lower antibody titers.
Article
Urology & Nephrology
Ana I. Sanchez Fructuoso, Andrea Bedia Raba, Eduardo Banegas Deras, Luis A. Vigara Sanchez, Rosalia Valero San Cecilio, Antonio Franco Esteve, Leonidas Cruzado Vega, Eva Gavela Martinez, Maria E. Gonzalez Garcia, Pablo Saurdy Coronado, Nancy D. Valencia Morales, Sofia Zarraga Larrondo, Natalia Ridao Cano, Auxiliadora Mazuecos Blanca, Domingo Hernandez Marrero, Isabel Beneyto Castello, Javier Paul Ramos, Adriana Sierra Ochoa, Carmen Facundo Molas, Francisco Gonzalez Roncero, Armando Torres Ramirez, Secundino Cigarran Guldris, Isabel Perez Flores
Summary: This multicentre study aimed to examine the efficacy and safety of SGLT2i treatment in DKTRs. The results showed that SGLT2i treatment was effective in controlling glycemia and had additional benefits in improving weight, blood pressure, anaemia, proteinuria, and serum levels of magnesium and uric acid. However, urinary tract infection was the most frequent adverse effect. The findings suggest that DKTRs can benefit from SGLT2i treatment, but female patients and those with a history of UTI need to be closely monitored.
CLINICAL KIDNEY JOURNAL
(2023)
Article
Biochemistry & Molecular Biology
Lucia Canamero, Adalberto Benito-Hernandez, Elena Gonzalez, Clara Escagedo, Maria Rodriguez-Vidriales, Maria del Mar Garcia-Saiz, Rosalia Valero, Lara Belmar, Maria Angeles de Cos, Maria Victoria Francia, Juan Carlos Ruiz, Emilio Rodrigo
Summary: The study aimed to investigate the relationship between Torque Teno Virus (TTV) load and exposure to immunosuppressive drugs in kidney transplantation (KTx) patients. The results showed that TTV load was not related to the exposure to maintenance immunosuppression drugs such as mycophenolic acid (MPA) and tacrolimus. However, TTV load could be a useful marker for predicting the risk of opportunistic infections after KTx.
Letter
Urology & Nephrology
M. Dolores Sanchez de la Nieta Garcia, Lucia Gonzalez Lopez, Paz Castro Fernandez, Minerva Arambarri Segura, Alberto Martinez-Calero, Marina Alonso Riano, Ana Sanchez-Fructuoso
Article
Urology & Nephrology
Emilio Rodrigo, Luis F. Quintana, Teresa Vazquez-Sanchez, Ana Sanchez-Fructuoso, Anna Buxeda, Eva Gavela, Juan M. Cazorla, Sheila Cabello, Isabel Beneyto, Maria O. Lopez-Oliva, Fritz Diekmann, Jose M. Gomez-Ortega, Natividad Calvo Romero, Maria J. Perez-Saez, Asuncion Sancho, Auxiliadora Mazuecos, Jordi Espi-Reig, Carlos Jimenez, Domingo Hernandez
Summary: In kidney transplant recipients with recurrent IgA nephropathy (IgAN), tubulo-interstitial inflammation (TII) contributes to an increased risk of chronic kidney disease stage 5 or death censored-graft loss (CKD5/DCGL), independently of other known variables. These findings suggest that adding TII to the clinical variables, along with the Oxford classification, may help identify IgAN patients at higher risk of graft loss who could benefit from intensified immunosuppression or specific IgAN therapies.
CLINICAL KIDNEY JOURNAL
(2023)
Article
Biology
Maria Kislikova, Maria Ana Batlle Lopez, Francisco Javier Freire Salinas, Jose Antonio Parra Blanco, Maria Pilar Garcia-Berbel Molina, Alejandro Aguilera Fernandez, Vicente Celestino Pinera Haces, Maria Teresa Garcia Unzueta, Adalberto Benito Hernandez, Juan Carlos Ruiz San Millan, Emilio Rodrigo Calabia
Summary: This study analyzed the influence of clonal hematopoiesis of indeterminate potential (CHIP) on the risk of heart disease and cardiovascular events in patients with chronic kidney disease (CKD). The results showed that different genes associated with CHIP had different risks of cardiovascular events.
Article
Health Care Sciences & Services
Araceli Faraldo-Cabana, Ana Sanchez-Fructuoso, Isabel Perez-Flores, Juan Vicente Beneit-Montesinos, Daniel Munoz-Jimenez, Belen Peix Jimenez, Sara Asensio Arredondo, Enriqueta Isabel Nuno Santana, Maria Jose Santana Valeros, Virginia Hidalgo Gonzalez, Fernando Gonzalez Garcia, Ismael Ortuno-Soriano
Summary: The aim of this study was to develop an information guide for adults with kidney transplants to assess its effectiveness in increasing adherence to healthy habits in a subsequent clinical trial.
JMIR RESEARCH PROTOCOLS
(2023)
Article
Urology & Nephrology
Jose Luis Santiago, Luis Sanchez-Perez, Isabel Perez-Flores, Maria Angeles Moreno de la Higuera, Natividad Calvo Romero, Elena Urcelay, Ana Isabel Sanchez-Fructuoso
Summary: Our study replicated the association of PTPRO-rs7976329*C allele with TCMR Banff grade < II, as reported in the GWAS study. Homozygous mutant genotypes of both polymorphisms seemed to increase the risk of TCMR Banff grade < II, especially in patients receiving Thymoglobulin induction therapy. Multivariate analysis confirmed the association of PTPRO-rs7976329 with TCMR Banff grade < II, independent of Thymoglobulin induction therapy, and CCDC67-rs10765602 association was observed only in patients not receiving Thymoglobulin induction therapy. No association of these polymorphisms with TCMR Banff grade >= II was observed in either the overall cohort or in the subgroups stratified by Thymoglobulin therapy.
JOURNAL OF NEPHROLOGY
(2023)